NFE2L2 and lung carcinoma: Targeting NRF2 by miR-144-3p inhibited tumor progression in melanoma and acute myeloid leukemia86, and increased the sensitivity of lung cancer cells to cisplatin87, indicating the role of miR‐144‐3p in oxidative homeostasis.